Tags

Type your tag names separated by a space and hit enter

Identifying Profiles of Patients With Bipolar I Disorder Who Would Benefit From Maintenance Therapy With a Long-Acting Injectable Antipsychotic.
J Clin Psychiatry. 2020 06 16; 81(4)JC

Abstract

People with bipolar I disorder experience an illness course marked by potentially disastrous manic episodes, disabling depressive episodes, and functional impairment. A frequent obstacle to wellness in these individuals is nonadherence to treatment. Long-acting injectable (LAI) antipsychotics have the potential to address nonadherence and thereby increase patients' chances at sustained recovery and normal psychosocial functioning. LAI formulations of 2 second-generation antipsychotics-aripiprazole monohydrate and risperidone-have received approval from the US Food and Drug Administration as monotherapy or adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder in adult patients. In a recent roundtable meeting, a panel of 4 experts discussed the use of these medications in bipolar I disorder. This Academic Highlights summarizes their discussion, which included the impact of functional impairment, the potential benefits of employing an LAI antipsychotic at earlier stages of bipolar illness, and the characteristics of patients who may be good candidates for treatment with an LAI antipsychotic.

Authors+Show Affiliations

Department of Psychiatry and Behavioral Sciences, University of New Mexico, Albuquerque, New MexicoDepartment of Psychiatry, Icahn School of Medicine, Mount Sinai, New York City, New YorkDepartment of Psychiatry, South Oaks Hospital, The Zucker School of Medicine at Hofstra/Northwell, Amityville, New YorkDepartment of Psychiatry, University of Texas Southwestern Medical Center, Dallas, Texas

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32558403

Citation

Tohen, Mauricio, et al. "Identifying Profiles of Patients With Bipolar I Disorder Who Would Benefit From Maintenance Therapy With a Long-Acting Injectable Antipsychotic." The Journal of Clinical Psychiatry, vol. 81, no. 4, 2020.
Tohen M, Goldberg JF, Hassoun Y, et al. Identifying Profiles of Patients With Bipolar I Disorder Who Would Benefit From Maintenance Therapy With a Long-Acting Injectable Antipsychotic. J Clin Psychiatry. 2020;81(4).
Tohen, M., Goldberg, J. F., Hassoun, Y., & Sureddi, S. (2020). Identifying Profiles of Patients With Bipolar I Disorder Who Would Benefit From Maintenance Therapy With a Long-Acting Injectable Antipsychotic. The Journal of Clinical Psychiatry, 81(4). https://doi.org/10.4088/JCP.OT19046AH1
Tohen M, et al. Identifying Profiles of Patients With Bipolar I Disorder Who Would Benefit From Maintenance Therapy With a Long-Acting Injectable Antipsychotic. J Clin Psychiatry. 2020 06 16;81(4) PubMed PMID: 32558403.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Identifying Profiles of Patients With Bipolar I Disorder Who Would Benefit From Maintenance Therapy With a Long-Acting Injectable Antipsychotic. AU - Tohen,Mauricio, AU - Goldberg,Joseph F, AU - Hassoun,Youssef, AU - Sureddi,Suresh, Y1 - 2020/06/16/ PY - 2020/6/20/entrez PY - 2020/6/20/pubmed PY - 2020/6/20/medline JF - The Journal of clinical psychiatry JO - J Clin Psychiatry VL - 81 IS - 4 N2 - People with bipolar I disorder experience an illness course marked by potentially disastrous manic episodes, disabling depressive episodes, and functional impairment. A frequent obstacle to wellness in these individuals is nonadherence to treatment. Long-acting injectable (LAI) antipsychotics have the potential to address nonadherence and thereby increase patients' chances at sustained recovery and normal psychosocial functioning. LAI formulations of 2 second-generation antipsychotics-aripiprazole monohydrate and risperidone-have received approval from the US Food and Drug Administration as monotherapy or adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder in adult patients. In a recent roundtable meeting, a panel of 4 experts discussed the use of these medications in bipolar I disorder. This Academic Highlights summarizes their discussion, which included the impact of functional impairment, the potential benefits of employing an LAI antipsychotic at earlier stages of bipolar illness, and the characteristics of patients who may be good candidates for treatment with an LAI antipsychotic. SN - 1555-2101 UR - https://www.unboundmedicine.com/medline/citation/32558403/Identifying_Profiles_of_Patients_With_Bipolar_I_Disorder_Who_Would_Benefit_From_Maintenance_Therapy_With_a_Long-Acting_Injectable_Antipsychotic L2 - http://www.psychiatrist.com/JCP/article/Pages/2020/v81/OT19046AH1.aspx DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.